Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report)’s stock price passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $85.81 and traded as low as $83.87. Henry Schein shares last traded at $84.96, with a volume of 1,711,282 shares trading hands.
Analysts Set New Price Targets
Several research firms have commented on HSIC. Citigroup reiterated a “buy” rating and issued a $112.00 price objective (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. BTIG Research raised their target price on shares of Henry Schein from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Barclays reaffirmed an “overweight” rating and set a $100.00 target price (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Barrington Research set a $104.00 price target on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, August 21st. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $93.57.
Get Our Latest Report on Henry Schein
Henry Schein Trading Down 1.5%
The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.76 and a current ratio of 1.33. The stock has a market capitalization of $9.39 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 1.51 and a beta of 0.87. The business has a fifty day simple moving average of $85.81 and a 200 day simple moving average of $81.59.
Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.20. The company had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.48 billion. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. The company’s revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.38 earnings per share. As a group, research analysts expect that Henry Schein, Inc. will post 5.55 EPS for the current year.
Hedge Funds Weigh In On Henry Schein
Hedge funds have recently bought and sold shares of the business. Southpoint Capital Advisors LP raised its stake in Henry Schein by 28.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after purchasing an additional 700,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Henry Schein by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after purchasing an additional 56,687 shares during the period. M.D. Sass LLC grew its position in shares of Henry Schein by 2.9% during the 1st quarter. M.D. Sass LLC now owns 1,273,316 shares of the company’s stock worth $93,843,000 after purchasing an additional 35,443 shares in the last quarter. Bank of America Corp DE grew its position in shares of Henry Schein by 5.9% during the 1st quarter. Bank of America Corp DE now owns 1,221,585 shares of the company’s stock worth $90,031,000 after purchasing an additional 68,593 shares in the last quarter. Finally, Defilade Capital Management L.P. increased its holdings in shares of Henry Schein by 94.8% during the first quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company’s stock worth $45,992,000 after purchasing an additional 303,615 shares during the period. 96.62% of the stock is owned by institutional investors.
Henry Schein Company Profile
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Further Reading
- Five stocks we like better than Henry Schein
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
